quinazolines has been researched along with Peripheral Nerve Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Egerton, N | 1 |
| Guba, GP; Tarasiuk, VK; Timko, NA | 1 |
| Azuma, T; Higa, S; Kishimoto, S; Mizuno, R; Sakoda, S; Suzuki, T; Tsujino, S; Watanabe, Y; Yoshida, H | 1 |
1 review(s) available for quinazolines and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
1 trial(s) available for quinazolines and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
4 other study(ies) available for quinazolines and Peripheral Nerve Diseases
| Article | Year |
|---|---|
The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury.
Topics: Animals; Antithrombins; Capillary Permeability; Central Nervous System Agents; Cervical Vertebrae; Disease Models, Animal; Fibrin; Hirudins; Hyperalgesia; Injections, Spinal; Male; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrroles; Quinazolines; Radiculopathy; Rats, Sprague-Dawley; Receptor, PAR-1; Spinal Cord | 2017 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
[The use of deoxypeganin hydrochloride in the combined treatment of patients with diseases of the peripheral nervous system].
Topics: Adult; Alkaloids; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscle Tonus; Peripheral Nervous System Diseases; Quinazolines | 1989 |
The aortic alpha 1-adrenergic receptor in familial amyloidotic polyneuropathy.
Topics: Adrenergic alpha-Antagonists; Amyloidosis; Aorta; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Quinazolines; Receptors, Adrenergic, alpha | 1988 |